Compare ATI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATI | ROIV |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United Kingdom |
| Employees | 7600 | 750 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 21.0B |
| IPO Year | 1996 | 2021 |
| Metric | ATI | ROIV |
|---|---|---|
| Price | $153.45 | $32.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $153.75 | $28.94 |
| AVG Volume (30 Days) | 1.7M | ★ 4.9M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $4,043,500,000.00 | $29,053,000.00 |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $9.02 | $744.61 |
| P/E Ratio | $176.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.42 | $10.71 |
| 52 Week High | $171.11 | $30.33 |
| Indicator | ATI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 70.29 |
| Support Level | $139.22 | $26.65 |
| Resistance Level | $167.10 | N/A |
| Average True Range (ATR) | 6.33 | 1.06 |
| MACD | -1.11 | 0.21 |
| Stochastic Oscillator | 27.47 | 93.22 |
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.